Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European regulators after a ...

Participants in the FORWARD-53 trial had clinically significant improvements in time-to-rise, among other metrics.

The Cambridge-based biotech's experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

Sarepta Therapeutics (NASDAQ:SRPT) announced Friday that the company and its partner Roche (OTCQX:RHHBY) expect to provide EU ...

The European Medicines Agency asked for three clinical trials to be placed on hold until the exact cause of death of a US ...

When her son reached three last year, a new name loomed over their lives — Duchenne Muscular Dystrophy (DMD), a ...

Amid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five DMD trials ...

One of the demands raised during the protests was access to 'Elevidys', a one-time gene therapy treatment that has the ...

Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the ...